Skip to content

IEMbase 0320: SCARB2-related glucocerebrosidase receptor deficiency

Scope

Field Value
IEMbase ID 320
Nosology 20.6.03.02
Gene SCARB2
External IDs OMIM:254900; ORPHA:163696
Generated mapping UNMAPPED
Candidate DisMech targets Fuzzy candidate Gaucher_Disease.yaml rejected; broad PME context only
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents this as SCARB2-related glucocerebrosidase receptor deficiency with alternate labels myoclonus-neuropathy syndrome and action myoclonus-renal failure syndrome. The characteristic row is myoclonic seizures. Additional clinical rows include dilated cardiomyopathy, dementia, polyneuropathy, and renal failure.

The biochemical row is beta-D-glucosidase enzyme testing, recorded as normal in the cached age strata. No treatment rows are present.

DisMech phenotype coverage

The generated fuzzy candidate is Gaucher_Disease.yaml, but this is a false positive. Gaucher disease is GBA1-related beta-glucocerebrosidase deficiency with beta-glucocerebrosidase activity, chitotriosidase, glucosylsphingosine, organomegaly, cytopenias, bone disease, and ERT/SRT treatment. IEMbase's normal beta-D-glucosidase row is a differentiating clue, not a reason to map AMRF to Gaucher disease.

Progressive_Myoclonus_Epilepsy.yaml mentions SCARB2 among rarer PME genes, but it is not a dedicated SCARB2/AMRF target and does not cover the renal failure syndrome as a standalone disease.

Concordance and completeness

Judgement: true missing SCARB2/AMRF target.

The local PME umbrella provides weak context for action myoclonus and myoclonic seizures. It is not sufficient for canonical mapping because the IEMbase record is a SCARB2 lysosomal-membrane disease with renal failure and polyneuropathy. Gaucher disease should be rejected despite lysosomal and glucocerebrosidase-adjacent terminology.

Curation actions

  • Do not map this record to Gaucher disease.
  • Add a standalone SCARB2/action myoclonus-renal failure syndrome target if the disease is prioritized.
  • Preserve normal beta-D-glucosidase as a differential diagnostic detail rather than modeling it as Gaucher-like enzyme deficiency.